What Are Senolytics? The Anti-Ageing Science Moving from Mouse Labs to Human Trials

There is a certain kind of cell in your body that has stopped dividing but refuses to die. It is not cancerous. It is not dead. It is something in between — a cell that has reached the end of its useful life, triggered an internal alarm, and entered a permanent state of arrested activity called cellular senescence.

In small numbers, these cells are actually useful. They appear at wound sites to help orchestrate repair, act as a brake on the early growth of tumours, and help shape organs during foetal development. In these contexts, senescence is a feature of biology, not a bug.

But as you age, senescent cells accumulate, and your immune system — which is supposed to clear them — becomes less efficient at doing so. By your sixties, seventies, and eighties, they are present throughout your body in significant numbers, secreting a toxic cocktail of inflammatory molecules into the surrounding tissue. This cocktail — the senescence-associated secretory phenotype, or SASP — damages neighbouring cells, disrupts tissue architecture, drives chronic inflammation, and contributes, according to a growing body of research, to virtually every major disease of ageing: heart disease, cancer, neurodegeneration, diabetes, osteoporosis, frailty.

Senescent cells are not the only cause of ageing. But they are one of its most actionable drivers. And in the past decade, a new class of drugs called senolytics — compounds that selectively kill senescent cells — has moved from mouse experiments to human clinical trials, with results that are scientifically extraordinary and, in some respects, more complicated than the early enthusiasm suggested. This is the full story: what senescent cells are, how they damage you, what senolytics do, what the human trials have actually found, and where the field is going.

What Is Cellular Senescence?

Cellular senescence is a state of stable, essentially permanent cell-cycle arrest — a cell that has stopped dividing and, under normal circumstances, cannot be persuaded to start again. The term was coined by the American cell biologists Leonard Hayflick and Paul Moorhead in 1961, when they observed that human fibroblasts in culture would divide a finite number of times — roughly 50 — and then stop, entering a state they called replicative senescence. That maximum number of divisions became known as the Hayflick limit.

Since then it has become clear that senescence can be triggered by many stimuli beyond telomere shortening. A 2025 review in Cell Death Discovery from researchers at Fudan University, Temple University, and King Abdulaziz University identified the primary triggers as DNA damage from radiation, oxidative stress, and genotoxic chemicals; telomere shortening; oncogene activation — the paradoxical situation in which switching on a cancer-promoting gene triggers senescence as a protective response; and mitochondrial dysfunction, which generates reactive oxygen species that damage DNA and signal for arrest.

At the molecular level, senescence is enforced by two main tumour-suppressor pathways: p53/p21 and p16/Rb. DNA damage and telomere shortening trigger a DNA-damage response that activates p53, which drives production of p21; p21 then blocks the cyclin-dependent kinases that would otherwise push the cell through division. The p16/Rb pathway works in parallel to the same end. Both converge on one outcome: a cell that cannot divide. Morphologically, senescent cells are recognisable — large, flattened, and granular, with elevated beta-galactosidase activity (a standard marker), accumulated DNA-damage foci, and the SASP.

The SASP: Why Senescent Cells Are So Damaging

The senescence-associated secretory phenotype is perhaps the most consequential feature of senescent cells for ageing biology. It is the mechanism by which a relatively small number of non-dividing cells can cause damage far beyond their immediate neighbourhood. The SASP is a complex mixture of secreted factors: pro-inflammatory cytokines including IL-6, IL-8, and TNF-α; matrix metalloproteinases that degrade the extracellular matrix; growth factors such as VEGF; and chemokines that recruit immune cells.

The consequences are wide-ranging. Locally, the SASP degrades the structural environment around the cell, disrupts neighbouring healthy cells, and can even induce senescence in those neighbours through a process called paracrine senescence — spreading the senescent state from cell to cell. Systemically, SASP factors enter the bloodstream and feed the chronic low-grade inflammation that characterises ageing, sometimes called inflammaging, now recognised as a major driver of age-related disease across nearly every organ system.

Crucially, the SASP is not a single fixed cocktail. Its composition is highly heterogeneous, varying by cell lineage, metabolic state, and the stressor that induced senescence, and recent work shows its inflammatory signalling is sustained by several nucleic-acid-sensing pathways. Senescent cells also deploy immune-evasion mechanisms that limit their clearance by cytotoxic lymphocytes and natural killer cells — which is part of why they accumulate with age even while the immune system remains partially functional, and part of why purely immunological approaches to clearing them may not be enough on their own.

The Mouse Experiments That Changed Everything

The case for targeting senescent cells was built primarily on a remarkable series of mouse experiments at the Mayo Clinic by James Kirkland, Jan van Deursen, and their collaborators, beginning around 2011. The landmark study, published in Nature in 2011 by van Deursen’s group, used a genetically engineered mouse in which senescent cells could be selectively eliminated — the cells expressed a drug-activatable suicide gene tied to p16Ink4a, a senescence marker. When the drug was given to aged mice, clearing their senescent cells, the animals showed remarkable improvements: delayed onset of cataracts, muscle wasting, and fat-tissue dysfunction. Clearing senescent cells did not just slow ageing — it appeared to reverse some of its features in animals that had already aged.

Subsequent experiments were even more striking. In 2016, Kirkland’s group showed that transplanting small numbers of senescent cells into young, healthy mice caused them to develop physical dysfunction and features of ageing — evidence that senescent cells are not merely a correlate of ageing but a causal driver. When senescent cells were cleared from naturally aged mice using early senolytic compounds, the animals showed improved physical function, reduced inflammation, and extended healthspan. The implication — that a single drug might delay or reverse multiple age-related diseases at once — became one of the most promising ideas in the history of geroscience, and the search for such drugs turned intense.

What Are Senolytics? The Drugs Being Developed

Senolytics are compounds that selectively induce apoptosis — programmed cell death — in senescent cells, while leaving healthy cells relatively unaffected. The selectivity arises from the biology of senescence itself: senescent cells, despite being growth-arrested, resist normal death signals because they upregulate pro-survival pathways. Senolytic drugs target those pathways. The first identified were dasatinib — a tyrosine-kinase inhibitor already approved for leukaemia — and quercetin, a plant flavonoid. Dasatinib targets pro-survival signals in certain senescent cell types, particularly fat-cell progenitors; quercetin hits different pathways across a broader range. Together, the combination known as D+Q showed greater activity than either alone and became the most widely studied senolytic regimen.

It is worth distinguishing senolytics from senomorphics. Senomorphics — including rapamycin and certain JAK inhibitors — reduce the damage caused by senescent cells without eliminating them, by suppressing SASP secretion. They are generally better tolerated but do not address the underlying accumulation of dysfunctional cells; senolytics aim to eliminate the problem at its source. Other senolytic compounds in various stages of development include navitoclax (ABT-263), a BCL-2 inhibitor with potent activity that unfortunately causes thrombocytopenia in humans; fisetin, a natural flavonoid in multiple trials for frailty and ageing; 17-DMAG, an HSP90 inhibitor; UBX0101, an MDM2/p53 inhibitor from Unity Biotechnology tested in knee osteoarthritis; and CAR-T-based senolytics, engineered immune cells developed at the Salk Institute and Cold Spring Harbor Laboratory.

What Human Trials Have Actually Found — The Honest Picture

The transition from remarkable mouse results to human trials has produced a picture that is scientifically important, genuinely promising in parts, and considerably more complicated than the initial enthusiasm suggested.

The good news: safety and biological activity. A study by researchers from Harvard Medical School, the Mayo Clinic, Cedars-Sinai, Beth Israel Deaconess, and the Marcus Institute for Aging Research found D+Q treatment both feasible and safe, with no serious adverse events. It evaluated intermittent dosing — two days on, twelve days off — over twelve weeks in older adults at risk for Alzheimer’s, as part of the STAMINA trial; the intermittent schedule reflects preclinical evidence that senolytics need not be continuously present to work

In the related SToMP-AD trial, plasma levels of both drugs rose, dasatinib was detected in cerebrospinal fluid in 80% of participants (confirming it reaches the brain), and plasma inflammatory markers including SASP factors fell after treatment. In STAMINA, reductions in plasma TNF-α significantly correlated with improvements in cognitive scores.

The complicated news: clinical outcomes are modest. An NIA-funded trial testing whether a senolytic combination could improve bone health in older women found only limited benefits versus control. Published in Nature Medicine, it suggested that using senolytics to reverse ageing effects in humans has, so far, only a subtle effect despite the dramatic mouse data. That Phase 2 randomised trial was the largest and most rigorous senolytic study to date, and its modest results were sobering. Separately, Unity Biotechnology’s UBX0101 for knee osteoarthritis failed to beat placebo in Phase 2, and the programme was discontinued.

What explains the gap between dramatic mouse results and more modest human outcomes? Several factors likely matter. Mice are not humans — their senescent-cell burden relative to body size differs greatly from ours. Trial durations may be too short to detect effects on long-term outcomes. The patient populations chosen may not have had a high enough senescent-cell burden to show dramatic responses. And the SASP’s heterogeneity means a single drug combination may not address the full spectrum of senescent cell types driving a given disease.

The Next Generation: CAR-T and Immune-Based Approaches

The limits of first-generation small-molecule senolytics have accelerated more targeted approaches. In 2023, researchers at Cold Spring Harbor Laboratory published in Nature Aging a proof-of-concept study showing that CAR-T cells — the engineered immune cells that transformed leukaemia treatment — could be designed to target and destroy senescent cells expressing the surface protein uPAR. In mouse models, these CAR-T senolytics improved metabolic function, extended healthspan, showed no apparent toxicity, and even reduced tumour burden in a lung-cancer model by exploiting the senescence that cancer therapy induces in tumour cells.

The Salk Institute group led by Juan Carlos Izpisua Belmonte has pursued a related strategy — partial cellular reprogramming using Yamanaka factors to reset the epigenetic age of cells, partly reversing senescence without fully dedifferentiating them; their 2023 work in Nature Aging demonstrated lifespan extension in progeria mice, though the path to humans remains long. More broadly, rather than bypassing the body’s own senescence-surveillance machinery, several groups are working to restore the natural killer cells and cytotoxic T lymphocytes that clear senescent cells in younger people — supplementing the immune system rather than replacing its job with drugs.

Senolytics and Specific Diseases: The Pipeline

Alzheimer’s and neurodegeneration. Senescent astrocytes, microglia, and neurons accumulate in the ageing brain and in Alzheimer’s patients. The SToMP-AD and STAMINA trials established that D+Q reaches the central nervous system and lowers SASP markers; larger efficacy trials are in planning.

Osteoporosis and musculoskeletal disease. Cellular senescence sits at the nexus of skeletal ageing, and selectively clearing senescent cells is being explored for age-related bone loss. The Phase 2 Nature Medicine trial showed only modest effects on bone-resorption markers, but multiple other trials remain active. Pulmonary fibrosis. Mayo Clinic ran the first human senolytic trial in idiopathic pulmonary fibrosis — a progressive, usually fatal lung-scarring disease with strong senescence involvement — and saw improvements in physical-function measures, though the trial was small and open-label.

Metabolic and cardiovascular disease. Senescence is both a cause and consequence of metabolic dysfunction, with visceral fat serving as a major source of SASP factors that impair insulin signalling; trials in diabetes, kidney disease, and cardiovascular complications are underway, though most are early-phase. Long COVID. Because SARS-CoV-2 appears to induce senescence in lung and other tissues, senolytic trials have been initiated in this population too.

The Honest Assessment: Where Are We Really?

Surveying the field in mid-2026, you could tell two very different stories. The optimistic one: a new class of drugs is showing biological proof-of-concept in humans, the science pointing to senescent cells as causal drivers of ageing is robust, and the field is moving from proof-of-concept toward efficacy trials. The cautious one: first-generation compounds have shown modest clinical effects at best, the dramatic mouse results have not translated cleanly, and real challenges in delivery, specificity, and biomarkers remain.

Both stories are true. The honest position is that the field is at an early stage — perhaps where cancer immunotherapy was in the early 2000s, when checkpoint inhibitors were showing biological activity and modest responses years before maturing into a transformative treatment.

The key challenges are clear. Biomarkers — reliable indicators of senescent-cell burden to select patients and confirm a drug is working — are not yet validated for clinical use. Selectivity — killing senescent cells without harming healthy ones — remains hard, as the thrombocytopenia of navitoclax illustrates; CAR-T cells and antibody-drug conjugates aim for greater precision. Tissue access is encouraging for the brain but a challenge elsewhere. And SASP heterogeneity means one-size-fits-all strategies may need to give way to tissue- and disease-specific approaches.

The connection to the broader genetics of ageing is direct. Senescent cells accumulate partly because DNA-repair mechanisms become less efficient with age, and telomere shortening — one of the primary triggers of senescence — is the subject of intense research. For the full story, see our article on telomeres and ageing: the genetic clocks inside every cell, and for how DNA damage connects to the disease where senescence plays its most complex role, see the genetics of cancer

 Epigenetic changes are both a cause and a consequence of senescence — the epigenetic-clock measures developed by Steve Horvath and others are strongly influenced by senescent-cell burden — a theme explored in our article on epigenetics and how your environment shapes your genes. Senolytics also sit within the wider effort to slow or reverse ageing itself, covered in our pieces on the real science of reverse ageing and what centenarian DNA reveals about longevity.

Frequently Asked Questions

Sources

• Cell Death Discovery — Hallmarks and Mechanisms of Cellular Senescence (2025)
• Biomolecules — Targeting Senescence: Senolytics and Senomorphics (2025)
• Clinical Trials of Senolytics in Alzheimer’s Disease (2025)
• National Institute on Aging — Senolytic Therapy and Bone Health (Nature Medicine, 2025)
• npj Aging — Senolytics: From Pharmacological Inhibitors to Immunotherapies (2024)
• Senescent Cells as a Target for Anti-Ageing Interventions (2025)